O titis media (OM) is a leading cause of health care visits, antibiotic prescriptions, and surgery. 1, 2 Its complications and sequelae are important causes of preventable hearing loss, particularly in developing countries. Reducing OM burden is warranted, and decision making should be based on the best available evidence.
Our ''Treatment and Complications'' Panel consisted of 11 clinician scientists in the field of OM who convened at the 2015 Post-Symposium Research Conference, following the 18th International Symposium on Recent Advances in Otitis Media, National Harbor, Maryland. We focused on articles on the treatment of OM and its complications that were published since the last panel report 3 and reviewed their implications for clinical practice. This article summarizes our main findings.
Methods
Panel members were assigned to review the literature on the management of one of the following disease entities: acute otitis media (AOM), recurrent AOM (rAOM), otitis media with effusion (OME), tympanostomy tube (TT) otorrhea, chronic suppurative otitis media (CSOM), and OM-related complications.
Each panel member designed a topic-specific keyword search strategy for the various electronic databases, including PubMed, Ovid Medline, the Cochrane Library, and Clinical Evidence (BMJ Publishing). Databases were searched from June 1, 2011, through March 31, 2015, restricted to articles with at least an abstract published in the English language. Publications cited in the previous review 3 were excluded. Searches were supplemented by additional relevant articles (including evidence-based practice guidelines) identified by members during discussion at the panel meeting.
We retrieved a total of 1935 records from the initial electronic database searches, of which 813 were excluded because of irrelevant title. Of 1122 articles retrieved for more detailed evaluation, 116 articles remained after excluding duplicates, irrelevant articles, narrative (nonsystematic) review articles, commentaries, and letters to the editor. Finally, after adding 2 more articles from reference lists, 118 articles were included in this article after final discussion.
Discussion
Acute Otitis Media ( Table 1) A high-quality placebo-controlled trial performed by Tapiainen et al 4 found that oral antibiotics shortened the period with middle ear effusion (MEE) after AOM. This trial was included in a 2015 Cochrane review update, 5 which showed that oral antibiotics for AOM reduce the proportion of children with abnormal tympanograms at 2 to 4 and 6 to 8 weeks but not at 3 months. Both this review 5 and a 2014 BMJ Clinical Evidence review 6 concluded that ''antibiotic treatment reduces AOM symptoms more quickly than placebo, but this benefit needs to be weighed against the increased risk of adverse events such as vomiting, diarrhea or rash.'' Type of antibiotic treatment. The 2014 BMJ review 6 summarized the evidence on antibiotic choice in children with AOM and concluded that ''we do not know whether any one antibiotic regimen should be used in preference to another, although amoxicillin may be more effective than macrolides and cephalosporin, and should be considered as first-line treatment.' ' The randomized clinical trial (RCT) performed by Casey et al, 7 which was included in the BMJ review, 6 showed that children treated with amoxicillin/clavulanate for 10 days Reported results for pain at 2 to 3 days correspond to 138 of 1186 and 180 of 1134 children (7 studies) in the oral antibiotics and placebo groups, respectively, and for adverse events to 283 of 1044 and 208 of 1063 children (8 studies) in the oral antibiotics and placebo groups, respectively. c Amox-clav: 80 mg/kg/d amoxicillin; cefdinir: 14 mg/kg/d. d Azithromycin ER: 60 mg/kg; amox-clav 90 mg/kg/d amoxicillin. Reported results are for 258 and 239 children with available bacteriological studies in the azithromycin ER and amox-clav groups on the test-of-cure days (12-14 days), respectively, and for 79 and 66 children with available bacteriological studies in the azithromycin ER and amox-clav groups at the end of the study period (41-64 days), respectively. reached ''clinical cure'' at 11 to 14 days more frequently than those treated with cefdinir for 5 days.
The RCT performed by Arguedas et al, 8 which was not included in the BMJ review, focused on children with tympanocentesis-positive bacteriological cultures at baseline (54% of children) and found no differences in ''clinical cure'' rates at 12 to 14 days between a single dose of azithromycin extended release and amoxicillin/clavulanate for 10 days.
A 2013 Cochrane review update 9 comparing 1 to 2 vs 3 to 4 daily doses of amoxicillin (with or without clavulanate) found no new studies on this topic, and a firm conclusion could not be drawn due to limited evidence.
Ototopical symptomatic agents. The 2014 BMJ review 6 found 2 low-quality trials suggesting that topical analgesics may be more effective than placebo at reducing ear pain 10 to 30 minutes after administration. Another systematic review 10 included the same 2 trials and 2 additional trials comparing anesthetic drops and herbal extracts drops. Again, quality of evidence was judged low, and the authors concluded that ''further studies with more rigorous methodology are needed to demonstrate the utility of ototopical agents.'' Systemic steroids. A 2013 systematic review 11 identified a 2003 RCT comparing 1 intramuscular dose of ceftriaxone combined with 5 days of either oral prednisolone (and/or antihistamine) or placebo for children with AOM. There was no significant benefit of systemic steroids.
Complementary and alternative medicine (CAM) treatments. An RCT performed by Sinha et al, 12 at high risk of bias, compared homeopathy vs conventional treatment and found similar numbers of patients cured at 21 days follow-up.
At-risk populations. No new studies were found on this topic.
Recurrent Acute Otitis Media ( Table 2) Culture-specific antibiotic treatment. Pichichero et al 13 conducted a prospective cohort study to determine whether strict AOM diagnostic criteria, tympanocentesis, and culture-specific antibiotic treatment of early life AOM episodes (individualized care) reduced the incidence of rAOM and TT placement. During 24 months of followup, rAOM incidence and TT placement were lower in children receiving individualized care than in legacy and community controls.
Surgical treatment. Kujala et al 14 randomized children aged 10 months to 2 years with rAOM, with and without MEE at baseline, into 3 groups: TTs only, TTs and adenoidectomy, or neither (control). Although there was a benefit of surgery over no surgery, the 2 surgical groups did not significantly differ with regard to number of failures for AOM recurrence and proportion of children with MEE for more than 2 months.
Lous et al 15 systematically reviewed the effectiveness of TTs in children with rAOM and included 5 RCTs published during 1981 to 1996. Because of heterogeneity, no meta-analysis was performed. Based on these trials, it was concluded that ''both TT and long-term treatment with antibiotics seems to prevent one attack of AOM, or keep one child out of three free from AOM in six months.'' Cheong and Hussain 16 conducted a systematic review of studies comparing the effect of prophylactic antibiotics, TTs, and adenoidectomy on rAOM. Eighteen studies were identified, of which 7 met the inclusion criteria. The authors concluded that all 3 treatment strategies had some benefits in preventing AOM recurrence, frequency of AOM episodes, and total time spent with AOM. Based on 2 studies in children aged 1 to 15 years, the authors concluded that adenoidectomy was beneficial only in children older than 2 years.
Boonacker et al 17 performed an individual patient data meta-analysis (IPDMA) of adenoidectomy for OM in children younger than 12 years. The authors included 15 RCTs of adenoidectomy alone or as an adjuvant to TTs in 1761 children and used a composite outcome including elements of both AOM and OME to summarize results. Analyzing different studies than those reviewed by Cheong et al, 16 they found that children younger than 2 years with rAOM may benefit from adenoidectomy, whereas in older children, no benefit was found.
CAM treatments. Marchisio et al 18 performed an RCT evaluating the risk of rAOM in relation to vitamin D deficiency and whether supplementation is effective in reducing AOM recurrences in otitis-prone children. Daily administration of 1000 IU of vitamin D for 4 months during the coldest months of the year was found to reduce AOM incidence.
Another RCT by Cohen et al 19 studied the effects of pro/ prebiotic-supplemented formula in infants 7 to 13 months old at high risk for AOM. Nasopharyngeal carriage of bacterial pathogens and AOM incidence were the same in the pro/prebiotic group and in infants who received a placebo formula.
A placebo-controlled trial by Vernacchio et al 20 found viscous xylitol solution 3 times daily for 12 weeks did not reduce AOM recurrences in otitis-prone infants and young children.
Otitis Media with Effusion ( Table 3) Oral antibiotics. A 2012 Cochrane review and meta-analysis of RCTs of antibiotics in children with OME 21 included 23 studies. The results of the review did not support routine use of antibiotics in children with OME; however, an effect on MEE clearance was seen at 1 to 3 months. There was no evidence of an effect of antibiotics on hearing, and none of the trials reported on speech, language, cognitive development, or quality of life (QoL) outcomes. The authors emphasized that the benefits must be weighed against the adverse effects of antibiotics for the individual and for society. One RCT of antibiotics for OME 22 has been published since the Cochrane review, showing some benefit of macrolides as an adjuvant to nasal steroids over nasal steroids alone in clearing MEE, as assessed by repeated tympanometry measurements. Steroids. Since the 2011 Cochrane review on oral or topical steroids in OME cited in the previous Treatment Panel, 3 1 additional placebo-controlled trial examined the effect of nasal steroids on OME in children with adenoid hypertrophy 23 ; tympanometry and audiometry outcomes were better in the steroid group. One trial evaluated the effect of intratympanic steroid injections in adults and older children with OME 24 and found some benefit on subjective symptoms and MEE. Neither of these studies reported on speech and language or other developmental outcomes.
Antihistamines and decongestants. A Cochrane review of antihistamines, decongestants, and their combinations for OME was updated in 2011. 25 While no clinical benefit was found for any of these treatments, adverse effects were more frequent than in those treated with placebo. A subsequent RCT 26 of montelukast and levocetirizine for OME found improvement in otoscopic sign scores after 1 month.
CAM treatments. Fixsen 27 conducted a systematic review of homeopathy in AOM and OME and found only 1 small study in children with OME. The author concluded that the evidence was incomplete and larger well-designed studies of CAM treatments for OM are needed. One RCT evaluated the effect of thermal therapy in children with OME. 28 The treatment group had better tympanometry outcomes at some of the follow-up visits.
Hearing aids. The psychosocial impact and parental attitude to hearing aids were compared between parents of children with OME treated by TTs and those treated with hearing aids; children treated with hearing aids did not suffer the bullying nor lower self-esteem anticipated by parents of children treated with TTs. 29 Auto-inflation. A Cochrane review of the effects of autoinflation on OME-associated hearing loss was updated in 2013. 30 Eight studies were included; meta-analysis showed small but positive effects of auto-inflation. The authors recommended auto-inflation during watchful waiting for OME resolution, in light of the absence of adverse effects and low cost. Since this Cochrane review, a new device for auto-inflation was tested in a small crossover study 31 Balloon dilatation of the eustachian tube. Miller and Elhassan 32 reviewed the literature on balloon dilatation of the eustachian tube; only uncontrolled case series in adults with OME were identified, with heterogeneous data collection methods and no long-term follow-up.
Tympanostomy tubes. No new trials of TTs for OME have been published since 2011, but there were new analyses based on existing data. Hellström et al 33 performed a systematic review and included 63 studies. They found highlevel evidence of the benefit of tubes for hearing and QoL for up to 9 months after treatment.
Berkman et al 34 reviewed the literature on treatment for OME and included 59 studies. They found that TTs are beneficial for clearing MEE for up to 2 years and for improving hearing for 6 months but found no evidence of a beneficial effect on language development. Eligible studies for inclusion in this meta-analysis were randomized controlled trials in children up to 12 years of age diagnosed with recurrent AOM and/or persistent otitis media with effusion in which adenoidectomy (with or without tympanostomy tubes) was compared with nonsurgical treatment or grommets alone. Baik and Brietzke 35 applied utility-based Markov decision theory modeling to the question of optimum duration of intubation with TTs. They found that intermediate-type TTs provide the greatest benefit compared with short-term TTs or permanent tubes, but this was influenced by the probability of needing a further set of TTs. Children not developing recurrent OME after a single set of TTs would be better treated with short-term tubes, but the challenge is to identify these children at first insertion.
Khodaverdi et al 36 reported long-term outcomes of TTs in children treated with a unilateral tube for bilateral OME 25 years earlier. They found no difference in hearing thresholds between the treated and untreated ear. In contrast, a retrospective study in children diagnosed with OME 5 years earlier found that hearing was poorer in those treated with TTs compared with children who did not receive TTs. 37 Adenoidectomy. The previously cited IPDMA by Boonacker et al 17 included patients with persistent OME. They found benefit of adenoidectomy in children with OME aged over 4 years but not in younger children.
Mikals and Brigger 38 reviewed the literature on adenoidectomy as an adjuvant to primary TT insertion. Five RCTs met the inclusion criteria; the pooled estimate of the rate of repeat TT surgeries for children undergoing primary adenoidectomy in addition to TTs was 20.4% vs 34.1% for children undergoing primary TTs only.
In the TARGET RCT, 39 children with OME were randomized to TTs only, adenoidectomy and TTs, or watchful waiting. Adenoidectomy with TTs extended the benefit to hearing through the second year of follow-up without evident diminution; the magnitude of this benefit was 4.2 dB hearing level (HL) over TTs alone. Adjuvant adenoidectomy reduced audiometric eligibility for revision surgery. In a retrospective case series of children treated with TTs, Gleinser et al 40 found a repeat TT insertion rate of 20%. Adenoidectomy performed at the first TT insertion for OME decreased the risk of repeat TT placement, especially for children aged 4 to 10 years.
At-risk groups. Children with cleft palate (CP) and Down syndrome (DS) are both more prone to developing OM, as well as to its complications and developmental sequelae, 41 yet they are excluded from most RCTs. Children with CP and DS are more likely to undergo treatment for OME, as are children with autistic spectrum disorder. 42 The systematic review on the effectiveness of OME treatments by Berkman et al 34 concluded that additional research is needed to support treatment decisions in these at-risk groups.
Kuo et al 43 undertook a systematic review of TTs for OME in children with CP. They identified 9 studies of high or moderate quality and found short-term benefit of TTs on hearing. Tierney et al 44 carried out a qualitative study of parents' experiences of OME treatment in children with CP and found that TTs were seen as a simple fix with some worries about complications. Hearing aids were associated with social stigma but were well tolerated by those who wore them.
Mohiuddin et al 45 evaluated the economic impact of TT insertion in children with OME and showed that in children with CP and bilateral OME, treatment with TTs is likely to be cost-effective. In a retrospective case series of more than 100 children with DS treated with TTs, Paulson et al 46 found hearing did not normalize after TTs in 14% of ears, signifying another underlying conductive cause or sensorineural hearing loss. Most children (64%) had a second set of TTs, and sequelae such as chronic perforations, atelectasis, and cholesteatoma were common.
Tympanostomy Tube Otorrhea and Complications of Tubes (Table 4)
Incidence of tympanostomy tube otorrhea. van Dongen et al 48 used a parental web-based questionnaire to collect retrospective data on tympanostomy tube otorrhea (TTO) incidence. Of 1184 children treated with TTs younger than 10 years, 52% had at least 1 TTO episode, 12% had recurrent TTO, and 4% had prolonged TTO. Independent predictive factors for TTO were young age, rAOM as the indication for TTs, recent history of recurrent upper respiratory infections (URIs) and having older siblings.
Treatment of TTO. In an RCT, van Dongen et al 49 compared 3 treatment modalities in children with acute TTO:
hydrocortisone-bacitracin-colistin eardrops, oral amoxicillinclavulanate suspension, or initial observation. At 2 weeks, antibiotic-steroid eardrops were more effective than oral antibiotics and initial observation in resolving otorrhea and were most cost-effective. 50 Cheng and Javia 51 retrospectively reviewed the management of children with methicillin-resistant Staphylococcus aureus (MRSA) TTO. Of medical treatments, fluoroquinolone eardrops were most successful. In 54% of patients, TTO resolved only after TT extrusion and/or removal, with or without TT replacement. 52 of prevention of postoperative TTO found 15 eligible RCTs, of which 7 were considered at low risk of bias. Four treatments were found to reduce the rate of otorrhea up to 2 weeks after surgery: multiple saline washouts during surgery, single application of topical antibiotic/steroid drops during surgery, prolonged application of topical antibiotic/steroid drops, and prolonged application of oral antibacterial agents/steroids. The authors concluded that if a surgeon has a high rate of postoperative otorrhea, either saline irrigation or single application of topical antibiotic drops during surgery could be an option to reduce that rate.
Prevention of early postoperative TTO. A Cochrane review
Park and Lee 53 followed 67 patients who received a mupirocin-coated TT and found early postoperative TTO occurred in only 1 patient, leading the authors to conclude that their product could be effective at preventing this problem. 54 reviewed the medical records of all children aged 2 to 4 years who had TTs for OME in 2 hospitals. Eighty-two had otomicroscopy 10 to 11 years later; myringosclerosis was the most common sequela. Of note, none had developed cholesteatoma.
Complications of TTs. Barati et al
Erdoglija et al 55 retrospectively studied complications within 18 months after TT insertion for OME in 487 children. Common complications included transient TTO, TT obstruction, and premature TT extrusion.
Saki et al 56 reviewed the medical records of 208 children followed for 12 to 18 months after TT insertion for OME. ''Transient'' and ''delayed'' otorrhea occurred in 13% and 8% of children, respectively. Complications after TT extrusion included atrophy, myringosclerosis, and persistent perforation.
Smillie et al 57 studied complication rates after TT insertion in 60 children with cleft lip and/or palate (CLP) and in 60 matched children without. TTO episodes were not more frequent in CLP children than in the control children. Other TT complications were more frequent in the control group.
Chronic Suppurative Otitis Media (Table 5)
Topical antibiotics. Morris 58 reviewed the literature on treatments for CSOM and cholesteatoma in adults and children. Although topical antibiotics seemed more effective than topical antiseptics in resolving otorrhea, the benefits of their use vs placebo in children is yet unclear.
A longitudinal cohort study in Greenland looked at evolution of CSOM. 59 Of 591 Inuit children originally examined in 1993-1994, 226 were followed up in 2009. Of 37 ears with CSOM at the initial examination, 39% had healed spontaneously. Fourteen ears not diagnosed originally with CSOM had CSOM at follow-up. One-third of children had CSOM, had undergone ear surgery, or had sequelae from CSOM at the follow-up visit.
An RCT comparing the effects of swimming vs no swimming in chlorinated pools in children with tympanic membrane (TM) perforations showed no differences in the proportion with discharge or in nasopharyngeal or middle ear microbiology of children who did or did not swim. 60 61 on the effects of zinc supplementation in preventing OM found mixed results in otherwise healthy children younger than 5 years living in lowand middle-income countries. Abbreviations: ABG, air-bone gap; ABx, antibiotic therapy; b-FGF, basic fibroblast growth factor; CI, confidence interval; CSOM, chronic suppurative otitis media; CR, cartilage reconstruction; FU, follow-up; LFS, longitudinal follow-up study; RCT, randomized controlled trial; RS, retrospective study; SR, systematic review; Sx, symptoms; TEM, tissue-engineered myringoplasty; TM, tympanic membrane; TMF, temporalis muscle fascia.
CAM. A Cochrane review
Surgical treatment. Two systematic literature reviews compared temporalis muscle fascia (TMF) with cartilage tympanoplasty. 62, 63 Both reviews reported better structural outcomes (fewer postoperative TM perforations) with a cartilage graft, but no better functional outcomes (similar hearing).
Novel adjuvant therapies. Hong et al 64 reviewed various adjuvant treatments for enhancing TM perforation repair, including biomolecules to stimulate the growth of perforation edges and bioengineered scaffolds. Most of the scaffold materials tested were safe and improved TM perforation healing rates. Kanemaru et al 65 performed an RCT (included in Hong et al 64 ) in 53 patients with chronic perforations comparing a gelatin sponge scaffold soaked in fibroblast growth factor (b-FGF) vs a gelatin sponge only following freshening of the perforation edge. They found significantly higher closure rate in the b-FGF group with no adverse events.
Guidelines for Treatment of Otitis Media
Acute otitis media and recurrent acute otitis media ( Table 6 ). Since 2011, guidelines on the diagnosis and management of AOM have been published across the world, including the United States, 66 Japan, 67, 68 Korea, 69 the Netherlands, 70 and Spain. 71 All guidelines emphasize the need for accurate diagnosis. Pain relief is considered paramount, and watchful waiting has continued to be an option in children with ''nonsevere'' AOM. Immediate antibiotics are reserved for children at high risk for an unfavorable outcome, with minor differences regarding definitions of ''at risk'' between guidelines.
For rAOM, reduction of risk factors (including day care attendance and tobacco smoke exposure) is encouraged, [66] [67] [68] active immunoprophylaxis with pneumococcal conjugate vaccines (PCVs) [66] [67] [68] [69] and influenza vaccine 66 is recommended, and long-term prophylactic antibiotics are discouraged. 66 Otitis media with effusion. Guidelines on OME were published in Korea, 69 the United States, 72 the Netherlands, 73 and Denmark. 74 All guidelines emphasize the importance of age-appropriate hearing testing when the diagnosis of OME is made. Watchful waiting is recommended initially, unless the child belongs to a high-risk group or has TM morphological findings that require surgical treatment. Follow-up is recommended at 3 months with repeated hearing testing. Medical treatment is discouraged, whereas surgical intervention, TTs initially, is recommended in selected cases, considering laterality (bilateral) and duration of the disease (.3 months), hearing status (varies across guidelines from .25 to .40 dB HL in the better ear), effect on the child's wellbeing, behavior, and development. The importance of involving parents in the decision-making process is emphasized in all guidelines. Concomitant adenoidectomy and/or tonsillectomy are recommended only if there is concomitant upper airway disease. Audiometric surveillance every 3 to 6 months is recommended whenever TTs are not inserted.
Impact of guidelines.
A range of studies have looked at the impact of local, national, and international guidelines on the treatment of AOM and URIs on clinical practice, particularly antibiotic prescribing rates. The studies vary in their design (ranging from a survey of private physicians to analysis of regional electronic databases), study population (at-risk groups vs general population), and outcomes (ranging from diagnosis to antibiotic prescribing). Overall, adherence to published guidelines seems suboptimal (eg, in the United Kingdom, Italy, Sweden, Turkey, Serbia, Greece, Israel, the United States). [75] [76] [77] [78] [79] [80] [81] [82] [83] In France, 84 guidelines have been effective in changing the antibiotic prescribing habits of pediatricians, and in Denmark, 85 general practitioners (GPs) to a large degree prescribe antibiotics appropriately. In the United Kingdom, the proportion of AOM episodes for which an antibiotic was prescribed was largely unchanged, 75 and the use of a broader spectrum antibiotic (amoxicillin plus clavulanic acid instead of amoxicillin) was the reason for diverging from recommendations in Hungary. 79 In a small UK audit, 76 adherence to OM guidelines seems independent of medical specialty: GPs, pediatricians, and otolaryngologists were equally noncompliant with antibiotic guidance. In contrast, Italian pediatricians were less likely to prescribe symptom-relieving drugs, such as decongestants and mucolytics, other than antibiotics, 77 and Greek physicians younger than 40 years seem to adhere better to guidelines than those 60 years or older. 80 All studies advocated continuing medical education as a means to improve the implementation of guidelines on antibiotic use, yet the optimal method to achieve this goal is unclear. Information alone seems ineffective, which could be attributed to either the insufficient educational power of these educational interventions or other barriers to their implementation (eg, cultural/social beliefs about the benefits and harms of antibiotics). 78 Targeting specific scenarios associated with immediate vs delayed or no antibiotics prescribing for AOM (eg, diagnosis on weekends vs weekdays, urgent care vs clinical setting, family care vs specialist care) may be effective in reducing unnecessary prescribing. 82 Electronic health record-based clinical decision support and performance feedback systems were found effective in improving adherence to OM guidelines; combining these 2 interventions, however, was no better than either delivered alone. 86 
Complications of Otitis Media
Acute mastoiditis. Differing trends in acute mastoiditis (AM) incidence have recently been reported, with small series suggesting an increase, 87, 88 while larger series suggesting no change or even a decline. [89] [90] [91] [92] [93] [94] Many of these studies have methodological limitations. A large US insurance claims database of children younger than 6 years suggested that AM incidence has declined following the introduction of PCVs, especially PCV-13. 94 Nevertheless, Streptococcus pneumoniae remains the most common cause of AM across the globe. 87, 90, 92, [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] Country-wide hospital data from Denmark and Sweden show that there has been no increase in the incidence of AM 96,103 since the introduction of guidelines to reduce antibiotic use for AOM, released a few years earlier.
Several case series show that 33% to 81% of patients diagnosed with AM had been treated with antibiotics prior to admission, suggesting that antibiotics administered for AOM treatment do not eliminate the risk of developing this complication.* While AM treatment traditionally involved cortical mastoidectomy, there is a recent trend toward nonsurgical management with intravenous antibiotics, either alone or combined with myringotomy and TT insertion and/or needle aspiration of the subperiosteal abscess. Contemporary case series report mastoidectomy rates between 29% and 93% of patients with mastoiditis; this variation may represent differences in clinical practice rather than disease severity. y In a review of 577 cases of AM from across Sweden, 10% of patients were successfully treated with antibiotics alone, 68% with antibiotics and myringotomy, and 22% with antibiotics and mastoidectomy. 103 In eastern Denmark, 96 183 of 214 (86%) pediatric AM cases were treated with myringotomy and antibiotics, and 31% also received TT. Sixty-eight children had a subperiosteal abscess, and all of these, except one, were treated by mastoidectomy. In a smaller case series from Greece, 13 of 24 (57%) children with a subperiosteal abscess were successfully treated with needle aspiration and myringotomy and did not require mastoidectomy. 107, 108 Chesney et al 109 developed an algorithm whereby in uncomplicated AM cases (without neurologic deficits or sepsis), computerized tomography (CT) scanning is postponed and treatment is initiated with intravenous antibiotics, with or without myringotomy and/or drainage or aspiration of any subperiosteal abscess. Failure to improve after 48 hours or clinical deterioration should prompt a CT scan to assess coexistent intracranial pathology, followed by mastoidectomy.
Intracranial complications. Retrospective reviews show that brain abscess is the most common intracranial complication of OM, 105, 110, 111 with an estimated incidence of 1 per million per annum. 112 A small Israeli case series found no reliable clinical signs or symptoms to distinguish children presenting with AM and coexistent intracranial complications from those without, confirming that imaging is warranted in cases not resolving promptly with conservative measures. 113 The role of anticoagulation in otogenic sigmoid sinus thrombosis remains controversial. Au et al 114 literature and found that anticoagulation was employed in 39 of 68 (57%) cases; 84% achieved partial or complete recanalization. However, 3 of 4 (75%) patients not treated with anticoagulation also achieved partial or complete recanalization. Reviews by Cochrane 115 and by the European Pediatric Neurology Society 116 found no RCTs of treatments of cerebral venous sinus thrombosis; both concluded that in the absence of contraindications, anticoagulation seems a safe and reasonable treatment. 115, 116 Several retrospective reviews report no complications of anticoagulation in patients with otogenic sinus thrombosis. [117] [118] [119] [120] [121] [122] 
Implications for Practice
While there were no studies that revolutionized treatment of OM in its various forms, the recent literature refines our knowledge of the effectiveness, and lack thereof, of various treatments. Accurate diagnosis of OM, in its various forms, and optimal management of ear pain are key to reducing overdiagnosis and overtreatment of this common condition in children. While antibiotics do shorten symptoms and duration of middle ear effusion, it is important to weigh their benefits and harms in OM. Watchful waiting is optional in mild to moderate AOM. Symptomatic hearing loss with OME is best treated with tympanostomy tubes. The benefit from adenoidectomy in OM is controversial and age dependent. Topical antibiotics are the treatment of choice in acute tube otorrhea. Novel molecular and biomaterial treatments as adjuvants to surgical closure of eardrum perforations are promising. There is insufficient evidence to support the use of CAM. From this review of the literature, it was apparent to the panel members that high-quality studies of OM treatments are needed in children particularly at risk for OM and its complications, as such children have so far been excluded from most research. Funding source: None.
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